0.96
-0.03(-3.03%)
Currency In USD
| Previous Close | 0.99 |
| Open | 0.96 |
| Day High | 0.99 |
| Day Low | 0.95 |
| 52-Week High | 2.22 |
| 52-Week Low | 0.54 |
| Volume | 25,084 |
| Average Volume | 178,848 |
| Market Cap | 10.24M |
| PE | -0.53 |
| EPS | -1.82 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 0.89 |
| Change | -0.03 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $10.88 as of October 19, 2025 at a share price of $0.96. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $39.34 as of October 19, 2025 at a share price of $0.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
GlobeNewswire Inc.
Sep 26, 2025 1:15 PM GMT
Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate
Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
GlobeNewswire Inc.
Sep 23, 2025 1:20 PM GMT
WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has engaged Lytham
Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk
GlobeNewswire Inc.
Sep 16, 2025 2:30 PM GMT
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supplemental Ne